Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 3 Jul 2017 |
| Novo Nordisk A/S - Share repurchase programme | 26 Jun 2017 |
| Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial | 23 Jun 2017 |
| Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial | 23 Jun 2017 |
| Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial | 22 Jun 2017 |